- The earnings showed a 7.4% increase in standalone profit after tax to ₹15.2 crore.
- The company’s overall revenue from operations declined 14.3% to ₹109.4 crore.
- Check out the latest news and updates on Business Insider.
Rossari recorded 14.3% fall in revenue to ₹109.4 crore but its net profit grew 7.4% to ₹15.2 crore as the cost of goods consumed in the making of its products fell by nearly a third. The input cost was the biggest saving in the latest earnings report.
Rossari makes popular household products like Vim, Rin, Ciff and Surf for the brand owners like Hindustan Unilever, Dabur, IFB, Arvind, Raymond, and many more to name a few. “In-home care, personal care and performance, we have 3 verticals. In one vertical, we make the ingredients, and these ingredients go into soap, detergents, paper, pulp, ceramic and tiles. They may constitute between 2-10% of the total product,” Rossari Biotech executive chairman and co-founder, Edward Menezes told Business Insider in a pre-listing conversation.
It was a bumper listing for Rossari, the shares made its debut on July 23, listing almost 57% higher on BSE against the issue price of ₹425. The IPO was held from July 13 to July 15 and was the first of its kind after COVID impacted the Indian stock-market.
Since then, shares have been riding on positive sentiments. It has gained nearly 8% since its listing and ended over 4% higher ahead of the earnings today.
The company was also a top mid and small-cap buy of mutual funds in July. According to reports, the mutual funds also bought the newly listed speciality chemical stock Rossari Biotech worth ₹407 crore.
SEE ALSO: Here’s a look at the top IPOs lined up to hit the market this year
Rossari Biotech IPO— 40 scientists, China, and other factors that make the share sale hot